Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
作者信息
Khan Sujoy
机构信息
Immunology and Allergy, Queen's Centre, Castle Hill Hospital, Cottingham, England.
出版信息
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
Abstract
摘要
相似文献
1
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
2
Baricitinib set to join the Covid-19 therapeutic arsenal?巴瑞替尼会加入新冠治疗药物库吗？
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
3
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.对信件的回复：巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？约根森等人
Clin Infect Dis. 2021 Dec 6;73(11):e3980-e3981. doi: 10.1093/cid/ciaa1210.
4
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？
Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208.
5
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.巴瑞替尼：在一项安慰剂对照试验中首个降低新冠肺炎死亡率的免疫调节治疗药物。
Lancet Respir Med. 2021 Dec;9(12):1349-1351. doi: 10.1016/S2213-2600(21)00358-1. Epub 2021 Sep 1.
6
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.巴瑞替尼在中重度 2019 冠状病毒病患者中的应用。
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.
7
Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?巴瑞替尼治疗2019冠状病毒病（COVID-19）：胰腺的朋友还是敌人？
Clin Infect Dis. 2021 Dec 6;73(11):e3977-e3978. doi: 10.1093/cid/ciaa1209.
8
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.巴瑞替尼治疗新冠病毒肺炎——满足一项未被满足的需求
N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.
9
Reply to letter to the editor: baricitinib and toxicity is a rare occurrence.致编辑的信的回复：巴瑞替尼与毒性是罕见事件。
Expert Opin Drug Saf. 2020 Oct;19(10):1371-1372. doi: 10.1080/14740338.2020.1812192. Epub 2020 Aug 24.
10
In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.在接受有创机械通气或体外膜肺氧合治疗的 COVID-19 患者中，加用巴瑞替尼联合常规治疗降低了全因死亡率。
Ann Intern Med. 2022 Jun;175(6):JC64. doi: 10.7326/J22-0033. Epub 2022 Jun 7.
本文引用的文献
1
Baricitinib set to join the Covid-19 therapeutic arsenal?巴瑞替尼会加入新冠治疗药物库吗？
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.用于治疗噬血细胞性淋巴组织细胞增生症（HLH）和重症新型冠状病毒肺炎（COVID-19）的Janus家族激酶（JAK）抑制剂
Am J Hematol. 2020 Dec;95(12):1448-1451. doi: 10.1002/ajh.25985. Epub 2020 Sep 30.
4
Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study.下呼吸道样本检测阴性后，支气管肺泡灌洗在排除 COVID-19 方面作用有限：一项多中心研究。
Eur Respir J. 2020 Oct 8;56(4). doi: 10.1183/13993003.01733-2020. Print 2020 Oct.
5
Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT.管理实时荧光定量聚合酶链反应（RT-PCR）检测结果为阴性但临床高度怀疑新型冠状病毒肺炎（COVID-19）的住院患者：胸部CT的实用价值及有限作用
Thorax. 2020 Jul;75(7):537-538. doi: 10.1136/thoraxjnl-2020-214916. Epub 2020 Apr 21.
Zotero 插件